BriaCell Therapeutics Corp. Warrant
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $2.4M
- Price
- $0.28
- % Change (Daily % change from the live per-ticker quote feed.)
- 0.00%
- Volume
- 64.9K
About
BriaCell Therapeutics Corp., a biotechnology company based in West Vancouver, Canada, is intensely focused on immuno-oncology, dedicated to engineering novel immunotherapies for cancer treatment. Its flagship compound, Bria-IMT, is a whole-cell cancer vaccine presently in Phase I/IIa clinical development, where it's being evaluated in conjunction with the investigational immunotherapy retifanlimab. The company's pipeline also includes Bria-OTS, a personalized, ready-to-use immunotherapy intended for advanced breast cancer, and BriaDx, a diagnostic tool for determining patient HLA types. BriaCell maintains a non-exclusive clinical trial collaboration with Incyte Corporation to explore the effects of combining various novel clinical candidates. Furthermore, a cooperative research and development agreement with the National Cancer Institute supports preclinical efforts to advance and test Bria-OTS cellular immunotherapy as a cancer therapy.
Quick stats
Shares outstanding8.7M
Computed float8.7M
Float / shares100.0%
Cash runway (months)5.3
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001610820
Websitehttps://www.briacell.com
AI Summary
AI-generated1/26
minorneutralclinical trial
BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting
BriaCell and its majority-owned subsidiary BriaPro will present four posters at the SITC 41st Annual Meeting, held November 4-8, 2026, in Phoenix, AZ.
The accepted abstracts cover preclinical research on BriaCell's Bria-OTS+ personalized off-the-shelf immunotherapy and BriaPro's tumor-targeted checkpoint inhibitors, including soluble CD80 (BP-80) and engineered CD80 variants.
This is a visibility event rather than a data readout; poster content will be posted to the company's scientific publications page after presentation.